Could Blockchain Ensure Integrity of Clinical Trial Data?

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable audit trail that makes it easy to spot any tampering with results - such as making the treatment look more effective or diminishing side effects.

"Everyone is talking about how blockchain is going to revolutionize many of the data challenges in medicine, and here is one use that finally might make sense," said Atul Butte, MD, PhD, who is the Priscilla Chan and Mark Zuckerberg Distinguished Professor and director of the Bakar Computational Health Sciences Institute at UCSF. "We think it could someday be useful for pharma companies running clinical trials."

The research was published February 22 in Nature Communications.

Blockchain technology utilizes an old computer science technique known as hashing, which creates a unique digital signature for each so-called block of data. The hashes accumulate sequentially, as new data is entered or changed, with each block depending on the last. The resulting "blockchain" creates an audit trail for regulators that is easy to decipher and validate, even without looking at the actual data.

Daniel Wong, a PhD candidate in Biological and Medical Informatics at UCSF, built the system to operate through a web portal, so that each time new data is entered on a given trial participant, the sender, receiver, timestamp, and file attachment containing the data, along with the hash of the previous block of data pertaining to that patient, is recorded onto a new block, with its own distinct signature.

Unlike the decentralized nature of most blockchain applications, this clinical trial prototype depends on having a regulator with centralized authority, such as the U.S. Food and Drug Administration, to operate the web portal, register all parties, and keep a ledger of the blockchain's hashes.

Data, including adverse events, would be reported to the regulatory agency in real time, which may provide a boost to the safety and efficiency of clinical trials. While the prototype makes allowances for data entry or other errors to be corrected, new data can only be appended to the existing chain, without erasing what was there before.

"It makes it really obvious when someone's changing something," Wong said. "You can see who put their hands on it, who made it, who changed it, and who received it."

Wong tested the system with a small subset of data from a real, previously run phase II trial included in ImmPort, a repository of open clinical trial data funded by the National Institutes of Allergy and Infectious Diseases (NIAID) that is managed by Butte's lab and collaborators.

After entering the original data, he logged in as the trial sponsor and tried to erase adverse events that had been reported for two patients in their case report forms. Instead of deleting those reports, however, the system appended his changes to the original data, making it clear who had tried to corrupt the forms, when it was done, and what had been changed.

Wong also tried corrupting the data stored from an earlier point in the trial, when patients were assigned to different treatment arms -- drug or placebo -- to make it look as though they had been given a different medication plan. But the blockchain ledger pinpointed exactly what had changed and when.

A prototype system like this reduces risks, but does not completely protect data from tampering. Even within a system enabled with this type of blockchain technology, the authors pointed out, it is still possible that those seeing patients at the point of care could enter wrong or incorrect data at the outset.

But blockchain technology could enable trials to be conducted under challenging conditions, or open doors to data exchanges that are more secure, more efficient, and more transparent for both researchers and the general public.

"A system built upon our prototype could be developed to enable oversight of international clinical trials, for example," Butte said. "And it could be expanded to provide more access to raw data for research scientists, the way we do with ImmPort, or deliver trial results to the public."

Daniel R Wong, Sanchita Bhattacharya, Atul J Butte.
Prototype of running clinical trials in an untrustworthy environment using blockchain.
Nature Communicationsvolume 10, Article number: 917 2019. doi: 10.1038/s41467-019-08874-y.

Most Popular Now

A New Machine Learning Model can Classif…

Machine learning has improved dramatically in recent years and shown great promise in the field of medical image analysis. A team of research specialists at Dartmouth's Norris Cotton Cancer Center...

Could Blockchain Ensure Integrity of Cli…

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable audit trail that makes it easy...

3D Child Welfare: How Data, Design and D…

Opinion Article by Rainer Binder, Managing Director, Global Employment and Social Services, Accenture Child welfare remains a pressing challenge for governments around the world, and the statistics are heart-breaking. In the...

Bringing more Human Intelligence to AI, …

The advent of data science, wireless connectivity and sensors, artificial intelligence (AI), and the Internet of Things (IoT) has raised the prospects for digital automation, smart hospital design and the...

Scotland's Digital Health Leaders Recogn…

Scotland's digital health champions have been recognised for their achievements at the Holyrood Connect Digital Health and Care Awards 2019. William Edwards, director of eHealth at NHS Greater Glasgow and...

DMEA 2019: International Exchange on Dig…

9 - 11 April 2019, Berlin, Germany. DMEA (formerly conhIT) is the industry's main event for digital healthcare. In that context, an international exchange of experiences and networking beyond national borders...

Philips to Expand its Radiology Informat…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has signed an agreement to acquire the Healthcare Information Systems business of Carestream Health...

Three Winners of 2019 Sandoz Healthcare …

Sandoz, a Novartis division, announced the winners of the 2019 Sandoz Healthcare Access Challenge (HACk). Sandoz HACk invites entrepreneurs and innovators in the field of digital technology to submit ideas...

UK Sales of Xanax and other Prescription…

Sales of prescription psychiatric drugs such as Xanax and diazepam via darknet online drug markets have increased in the UK at an alarming rate, according to new research by the...

Accenture Wins GLOMO Award for Virtual R…

The Accenture (NYSE: ACN) Virtual Experience Solutions (AVEnueS) has won "Best Mobile VR or AR" at the GSMA GLOMO Awards 2019. The award was presented at MWC19 Barcelona.

Study Finds Robots can Detect Breast Can…

Breast cancer is the most common cancer in women, and despite important improvements in therapy, it is still a major cause for cancer-related mortality, accounting for approximately 500,000 annual deaths...